Vertex Pharmaceuticals VRTX
Biopharmaceuticals (cystic fibrosis). Vertex Pharmaceuticals Incorporated, listed on NASDAQ.
Based on the FY2025 annual report (Jan 2025 – Dec 2025)
Vertex Pharmaceuticals' market cap is
about $137.5 billion.
#78 by market cap among 289 companies, based on the Nov 5, 2026 close. FY2025 revenue was $12.0013B.
- Share price (close)
- $542.50
- P/E ratio
- 35.4x
- Market cap
- $137.5B
- Revenue
- $12.0013B
- Operating income
- $4.1733B
- Net income
- $3.9532B
- Free cash flow
- $3.1938B
- Total assets
- $25.643B
- Dividends paid
- —
- Dividend per share
- —
- Dividend yield
- —
- Shares outstanding
- 253,991,224 shares
Size, put in perspective
Calculated from the FY2025 annual report, spread evenly over 365 days.
Where the revenue went
Revenue is set at 100% and split into what went to costs, R&D, operating expenses and taxes, and what was left as profit.
- Cost of revenue13.8%
- R&D32.6%
- SG&A and other18.9%
- Taxes, interest & other1.8%
- Net income32.9%
Profitability and stability
Each figure comes with its rank among 300 companies. The further right the dot, the higher the rank.
- Revenue growthHow much revenue grew from the previous fiscal year
- +8.9%
- #131 of 299
- Revenue is growing steadily. The median across 299 companies is +7.9%.
- Operating marginShare of revenue kept as profit from the core business
- 34.8%
- #34 of 231
- 34.8% of revenue was kept as operating profit, which is very high. The median across 231 companies is 19.2%.
- Net marginShare of revenue left as profit after interest and taxes
- 32.9%
- #23 of 298
- After taxes, 32.9% of revenue was left as net income. The median across 298 companies is 14.0%.
- FCF marginShare of revenue left as cash after capital spending
- 26.6%
- #57 of 261
- Plenty of cash is left after capital spending. The median across 261 companies is 15.8%.
- ROEHow much profit the company earned on shareholders' equity in a year
- 22.5%
- #107 of 276
- Earns a lot relative to its equity. The median across 276 companies is 16.8%.
- Debt-to-equityLiabilities relative to equity. Lower means less debt
- 37.4%
- #14 of 244
- Liabilities are smaller than equity. The median across 244 companies is 159.6%.
Revenue and profit over time
Gray bars show revenue and the green part inside shows net income. The number above each bar is revenue (abbreviated) and the number below is net margin. Hover over a bar to see the exact amounts.
Where the cash went
Unlike profit, cash flow is money that actually came in and went out.
- Cash from operations$3.6314B
- Capital spending−$437.6M
- Free cash flow (FCF)$3.1938B
Whose money funds the assets
The company's assets, split into borrowed money (liabilities) and shareholders' money (equity).
- Total assets$25.643B
- Total liabilities$6.9772B
- Total equity$18.6658B
- Cash and equivalents$5.0848B
Compared with similar companies
Based on each company's latest annual report, so fiscal year ends may differ.
Compare in detail| Company | Annual revenue | Net income | Revenue growth | Operating margin | Net margin |
|---|---|---|---|---|---|
| Vertex PharmaceuticalsVRTX | $12.0013B | $3.9532B | +8.9% | 34.8% | 32.9% |
| ModernaMRNA | $1.944B | −$2.822B | −39.9% | −158.1% | −145.2% |
| RegeneronREGN | $14.3429B | $4.5049B | +1.0% | 24.9% | 31.4% |
| Gilead SciencesGILD | $29.443B | $8.51B | +2.4% | 34.0% | 28.9% |
| AmgenAMGN | $36.751B | $7.711B | +9.9% | 24.7% | 21.0% |
What the company does
Vertex dominates the market for cystic fibrosis treatments and is expanding into non-opioid pain medicine and gene therapies.
The fiscal year ends around December each year.
Related companies: Moderna, Regeneron, Gilead Sciences, Amgen
Financial statements
Last 5 fiscal years. Currency: US dollars.
Show the table
| Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 7.5744B | 8.9307B | 9.8692B | 11.0201B | 12.0013B |
| Cost of revenue | 904.2M | 1.0803B | 1.2622B | 1.5305B | 1.6513B |
| Gross profit | 6.6702B | 7.8504B | 8.607B | 9.4896B | 10.35B |
| R&D expense | 1.9378B | 2.5403B | 3.1629B | 3.6303B | 3.9095B |
| Operating income | 2.7821B | 4.3074B | 3.832B | −232.9M | 4.1733B |
| Pretax income | 2.7304B | 4.2324B | 4.3798B | 248.5M | 4.6432B |
| Net income | 2.3421B | 3.322B | 3.6196B | −535.6M | 3.9532B |
| EPS (diluted) | $9.01 | $12.82 | $13.89 | $-2.08 | $15.32 |
| Operating cash flow | 2.6435B | 4.1299B | 3.5373B | −492.6M | 3.6314B |
| Capital expenditures | 235M | 204.7M | 200.4M | 297.7M | 437.6M |
| Free cash flow (FCF) | 2.4085B | 3.9252B | 3.3369B | −790.3M | 3.1938B |
| Total assets | 13.4325B | 18.1509B | 22.7302B | 22.5332B | 25.643B |
| Total liabilities | 3.3325B | 4.2382B | 5.1498B | 6.1236B | 6.9772B |
| Total equity | 10.1B | 13.9127B | 17.5804B | 16.4096B | 18.6658B |
| Cash and equivalents | 6.795B | 10.504B | 10.3691B | 4.5696B | 5.0848B |
| Original filing | 10-K | 10-K | 10-K | 10-K | 10-K |
Source: SEC EDGAR filings for Vertex Pharmaceuticals Incorporated · CIK 0000875320 · US-GAAP